Table 2.
Association between protein expression and clinicopathological variables
| Variables | Calpastatin | Calpain-1 | Calpain-2 | Calpain-4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | P value | Low | High | P value | Low | High | P value | Low | High | P value | |
| Age | ||||||||||||
| ≤ 62 | 97 (20.7%) | 143 (30.5%) | 0.026 | 50 (10.7%) | 190 (40.5%) | 0.705 | 45 (9.6%) | 195 (41.7%) | 0.880 | 67 (14.3%) | 173 (36.9%) | 0.215 |
| > 62 | 116 (24.7%) | 113 (24.1%) | 51 (10.9%) | 178 (38.0%) | 44 (9.4%) | 184 (39.3%) | 76 (16.2%) | 153 (32.6%) | ||||
| Histological subtypes | ||||||||||||
| HGSC | 122 (26.0%) | 165 (35.2%) | 0.004 | 38 (8.1%) | 249 (53.1%) | < 0.001a | 54 (11.5%) | 233 (49.8%) | 0.334a | 83 (17.7%) | 204 (43.5%) | 0.003a |
| Mucinous | 24 (5.1%) | 21 (4.5%) | 14 (3.0%) | 31 (6.6%) | 11 (2.4%) | 34 (7.3%) | 14 (3.0%) | 31 (6.6%) | ||||
| Endometrioid | 25 (5.3%) | 30 (6.4%) | 20 (4.3%) | 35 (7.5%) | 6 (1.3%) | 48 (10.3%) | 14 (3.0%) | 41 (8.7%) | ||||
| CCC | 31 (6.6%) | 13 (2.8%) | 25 (5.3%) | 19 (4.1%) | 12 (2.6%) | 32 (6.8%) | 25 (5.3%) | 19 (4.1%) | ||||
| LGSC | 7 (1.5%) | 17 (3.6%) | 3 (0.6%) | 21 (4.5%) | 3 (0.6%) | 21 (4.5%) | 5 (1.1%) | 19 (4.1%) | ||||
| SBOT | 4 (0.9%) | 10 (2.1%) | 1 (0.2%) | 13 (2.8%) | 3 (0.6%) | 11 (2.4%) | 2 (0.4%) | 12 (2.6%) | ||||
| Grade | ||||||||||||
| 1 | 16 (3.4%) | 21 (4.5%) | 0.796 | 8 (1.7%) | 29 (6.2%) | 0.415 | 8 (1.7%) | 29 (6.2%) | 0.915 | 9 (1.9%) | 28 (6.0%) | 0.196 |
| 2 | 31 (6.6%) | 42 (9.0%) | 20 (4.3%) | 53 (11.3%) | 14 (3.0%) | 59 (12.6%) | 17 (3.6%) | 56 (12.0%) | ||||
| 3 | 166 (35.5%) | 192 (41.0%) | 73 (15.6%) | 285 (60.9%) | 67(14.3%) | 290 (62.1%) | 117 (25.0%) | 241 (51.5%) | ||||
| Response to platinum-based chemotherapy | ||||||||||||
| Pt sensitive | 96 (%) | 121 (%) | 0.278 | 46 (%) | 171 (%) | 0.854 | 45 (%) | 171 (%) | 0.630 | 62 (%) | 155 (%) | 0.644 |
| Pt resistance | 14 (%) | 26 (%) | 9 (%) | 31 (%) | 7 (%) | 33 (%) | 10 (%) | 30 (%) | ||||
| Stage | ||||||||||||
| I | 83 (18.0%) | 86 (18.7%) | 0.217 | 51 (11.1%) | 118 (25.6%) | 0.002 | 35 (7.6%) | 133 (28.9%) | 0.572 | 52 (11.3%) | 117 (25.4%) | 0.969 |
| II | 24 (5.2%) | 30 (6.5%) | 13 (2.8%) | 41 (8.9%) | 7 (1.5%) | 47 (10.2%) | 17 (3.7%) | 37 (8.0%) | ||||
| III | 82 (17.8%) | 123 (26.7%) | 28 (6.1%) | 177 (38.4%) | 40 (8.7%) | 165 (35.9%) | 59 (12.8%) | 146 (31.7%) | ||||
| IV | 18 (3.9%) | 15 (3.3%) | 8 (1.7%) | 25 (5.4%) | 5 (1.1%) | 28 (6.1%) | 10 (2.2%) | 23 (5.0%) | ||||
| Stage | ||||||||||||
| Confined tumour (I) | 83 (18.0%) | 86 (18.7%) | 0.167 | 51 (11.1%) | 118 (25.6%) | 0.001 | 35 (7.6%) | 133 (28.9%) | 0.425 | 52 (11.3%) | 117 (25.4%) | 0.766 |
| Tumour spread (II–IV) | 124 (26.8%) | 168 (36.4%) | 49 (10.6%) | 243 (52.7%) | 52 (11.3%) | 240 (52.2%) | 86 (18.7%) | 206 (44.7%) | ||||
| Distant metastasis | ||||||||||||
| Absence (stage I–III) | 189 (41.0%) | 239 (51.8%) | 0.248 | 92 (20.0%) | 336 (72.9%) | 0.712 | 82 (17.8%) | 345 (75.0%) | 0.567 | 128 (27.8%) | 300 (65.1%) | 0.962 |
| Presence (stage IV) | 18 (3.9%) | 15 (3.3%) | 8 (1.7%) | 25 (5.4%) | 5 (1.1%) | 28 (6.1%) | 10 (2.2%) | 23 (5.0%) | ||||
| Residual disease | ||||||||||||
| No residual tumour | 114 (27.5%) | 143 (34.5%) | 0.958 | 73 (17.6%) | 184 (44.3%) | < 0.001 | 55 (13.3%) | 201 (48.6%) | 0.677 | 76 (18.3%) | 181 (43.6%) | 0.982 |
| Residual tumour < 2 cm | 23 (5.5%) | 27 (6.5%) | 5 (1.2%) | 45 (10.8%) | 11 (2.7%) | 39 (9.4%) | 15 (3.6%) | 35 (8.4%) | ||||
| > 2 cm | 47 (11.3%) | 61 (14.7%) | 14 (3.4%) | 94 (22.7%) | 19 (4.6%) | 89 (21.5%) | 33 (8.0%) | 75 (18.1%) | ||||
Pt Platinum
aHave expected count less than 5. Significant P values are indicated by bold type